Solid tumors refractory. Medical search. Frequent questions

Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared XGEVA (TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing skeletal-related events (SREs). (amgen.com)

To obtain information about the tolerability of palbociclib in children and adolescents with relapsed or refractory cancer. (clinicaltrialsgps.com)

The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. (oncnursingnews.com)
The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, according to the updated results of a phase 1 study (NCT03220347) presented during the 2020 ESMO Virtual Congress. (oncnursingnews.com)
CC-90010 was well-tolerated and showed preliminary antitumor activity in heavily pretreated patients with advanced solid tumors and relapsed DLBCL," Victor Moreno Garcia, PhD, director of Clinical Research at the Phase 1 Trials Unit START at University Hospital Fundación Jiménez Díaz, said in a presentation during the meeting. (oncnursingnews.com)
According to ImmuneOncia, IMC-002 is expected to help patients with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. (prnewswire.com)

Treatment protocols for osteogenic sarcoma are provided below, including general and first-line treatment recommendations and recommendations for second-line therapy for relapsed or refractory disease. (medscape.com)

To learn more about available clinical trials related to brain and spinal tumors, contact us at [email protected] or 513-636-2799. (cincinnatichildrens.org)

This article in Cancer Discovery reviews the types of solid tumors that express mesothelin, and the potential of mesothelin-directed CAR T-cell therapy to treat such malignancies. (aacr.org)

The agent was found to lead to tumor reduction when evaluated in xenograft models and encouraging activity in patients with advanced malignancies.2 Because BET proteins are key players in the regulation of MYC oncogene expression, investigators hypothesized that CC-90010 may represent a potential effective option for patients with high-grade B-cell lymphoma, particularly those who have MYC rearrangements. (oncnursingnews.com)
PURPOSE: This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. (cincinnatichildrens.org)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. (clinicaltrialsgps.com)
TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. , (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. (biospace.com)
Subject to certain exclusion criteria, this study is enrolling participants, ages 6 months to 21 years, who have recurrent or refractory solid tumors, including central nervous system tumors and lymphoma, for which no standard therapy is available. (chp.edu)
The PLAT trials are phase 1 and 2 clinical trials testing CAR T-cell therapy in children, teens and young adults with relapsed or refractory acute leukemia or lymphoma. (seattlechildrens.org)

In retrospect, the fact that cancer was viewed as a genetic disease for so long was likely an artifact of focus and technology: Chromosomal changes began to be detectable before we understood epigenetics at a molecular level, and the early focus on familial cancer and rapidly induced viral tumors favored the discovery of mutational carcinogenesis, which has largely colored our views over the past three decades ( 3, 4 ). (aacrjournals.org)
But in practice, immunotherapies have largely advanced either without any companion diagnostic biomarkers, or with specific, single-parameter tests that gauge PD-L1 expression, microsatellite instability, or tumor mutational burden (TMB) - all of which are recognized as capturing only some of the variability in immunotherapy response, and as such, potentially missing responders or mistakenly identifying non-responders. (genomeweb.com)
And TMB has been shown to associate with response across many tumor types, resulting in the recent histology-agnostic US Food and Drug Administration approval of pembrolizumab (Merck's Keytruda) as a treatment for adult and pediatric patients with refractory solid tumors and a high mutational burden. (genomeweb.com)
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. (cdc.gov)
Phase study of the tumor mutational burdenTtmb mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma. (bvsalud.org)
The coverage decision for F1CDx dramatically expands on current profiling and will provide information for tumors where mutational testing is not common, such as pancreatic and prostate cancer. (medscape.com)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. (memorialcare.org)
complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in cell cycle genes. (clinicaltrialsgps.com)
I. To estimate the progression free survival in pediatric patients treated with palbociclib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in alterations in cell cycle genes. (clinicaltrialsgps.com)
His primary clinical focus is on pediatric solid tumors, including neuroblastomas, tumors of the kidneys, and rare solid tumors of childhood. (spotify.com)
In the BrainChild-03 trial, a patient's own T cells are reprogrammed to recognize and target the protein B7-H3, which is expressed on many pediatric CNS tumors but not healthy brain tissue. (seattlechildrens.org)

To determine the maximum-tolerated or recommended phase II dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and immunomodulatory effects of lenalidomide in children with recurrent or refractory solid tumors or myelodysplastic syndrome (MDS). (nih.gov)
This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. (cincinnatichildrens.org)
Through this Children's Oncology Group (COG) study, researchers are evaluating the effectiveness of drug pevonedistat (MLN4924) used along with two other drugs to fight recurrent tumors and tumors that will not respond to standard therapy. (chp.edu)
ENLIGHTen-01 is a phase 1 clinical trial testing CAR T cells administered with UB-TT170, a small molecule fluorescein tag that targets folate receptors to mark tumors for clearance by CAR T cells, that is open to teens and young adults with recurrent or refractory osteosarcoma. (seattlechildrens.org)
For recurrent tumors, surgery combined with radiotherapy, chemotherapy, and/or targeted therapy can be used for control. (bvsalud.org)

Recent work has focused on the signaling, metabolic, and transcriptional mechanisms of T cell regulation as well as tumor-elicited innate and adaptive immune responses, and how this knowledge can be translated for novel cancer immunotherapy. (spotify.com)
Since these patients do not respond as well to chemotherapy and immunotherapy, there is a need to find a more targeted therapy for the subset of patients whose tumors harbor NRG1 fusions, Carrizosa concludes. (onclive.com)
NEW YORK - Researchers have identified new strategies for predicting response to immunotherapy, using approaches that integrate genomic and molecular signals, immune cell phenotypes, and other biological markers related to the body's anti-tumor immune response. (genomeweb.com)
One of these strategies was discussed by Kevin Litchfield at the University College London Cancer Institute, whose team conducted a meta-analysis using publicly available exome and transcriptome data from more than 1,000 patients with various tumor types enrolled in multiple immunotherapy studies. (genomeweb.com)
Given the success of CAR T-cell therapies for blood cancers, the most anticipated next step in the field is the development of this type of immunotherapy for solid tumors. (aacr.org)
Read more about how T-cell immunotherapy for CNS tumors works . (seattlechildrens.org)

These data include the most recent anti-tumor activity data from the trial's first four dose escalation cohorts and initial pharmacokinetic/pharmacodynamic (PK/PD) data from the fifth dose escalation cohort. (tmcnet.com)
Updated anti-tumor activity data on these participants are described below and incorporated into swimmer and waterfall plots in Medicenna's investor presentaion . (tmcnet.com)
The selective delivery of exatecan to tumors led to extremely potent and durable anti-tumor activity in a range of xenograft models with minimal to no side effects relative to the unconjugated exatecan warhead, equimolar amounts of which are poorly tolerated. (globenewswire.com)

Cohorts of children with solid tumors received lenalidomide once daily for 21 days, every 28 days at dose levels of 15 to 70 mg/m(2)/dose. (nih.gov)
Two cohorts of patients received the 45-mg dose of CC-90010: cohort 1 was comprised of 14 patients with relapsed/refractory DLBCL and cohort 2 was comprised of 1 patient with advanced basal cell carcinoma and 1 patient with NUT midline carcinomas. (oncnursingnews.com)
Part 2 is a Phase 1b, open-label, dose-expansion study of five prespecified tumor cohorts to assess preliminary antitumor activity of IMGS-001 in patients that are refractory or intolerant to other appropriate prior standard therapies. (drugtrialsformoney.com)
As of February 7, 2020, 11 patients with refractory solid tumors were treated with the combination across 3 different dosing cohorts. (biospace.com)
Collectively, these findings fuel our enthusiasm as we look forward to upcoming readouts from ABILITY's Phase 2 expansion cohorts, which will evaluate an optimal dose in less advanced cancer and in patients with tumor types that are most likely to benefit from MDNA11. (tmcnet.com)
As previously reported, tumor control was achieved in five of fourteen evaluable participants in ABILITY's first four (low and mid) dose escalation cohorts. (tmcnet.com)

In a phase II trial reported in the Journal of Clinical Oncology , Fu et al found that the WEE1 kinase inhibitor adavosertib was active in patients with refractory solid tumors with CCNE1 amplification, with evidence of increased activity in epithelial ovarian cancer. (ascopost.com)
Tumor types included epithelial ovarian cancer in 14 patients, breast cancer in 3, uterine cancer in 3, and 10 different types in 1 patient each. (ascopost.com)
The investigators concluded, "Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification, especially in epithelial ovarian cancer. (ascopost.com)

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with relapsed or refractory solid tumors or myelodysplastic syndromes. (stanford.edu)
Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking blood flow to the cancer. (stanford.edu)

This ongoing Phase 1b trial ( NCT03905148 ) is an open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics (PK) and antitumor activities of mirdametinib in combination with lifirafenib, BeiGene's RAF dimer inhibitor, in patients with advanced or refractory solid tumors harboring RAS mutations, RAF mutations, and other MAPK pathway aberrations. (businesswire.com)
The combination showed antitumor activity in patients with various KRAS, NRAS, and BRAF mutations across several solid tumor types, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and endometrial cancer. (businesswire.com)
The safety, tolerability, PK parameters, and preliminary antitumor activity of IMGS-001 will be assessed in adult patients with advanced solid tumors refractory to appropriate standard of care (SOC) treatments. (drugtrialsformoney.com)
It exhibits potent antitumor activity by activating tumor-infiltrating CD8 + and CD4 + T cells and has a better therapeutic window relative to recombinant human IL-2. (genengnews.com)
Challenges include finding the right target to direct the T cells, the ability to expand in an often-immunosuppressive tumor microenvironment, yielding an effective antitumor response, and avoiding adverse side effects. (aacr.org)

In the latest version of the guidelines released in November 2020, surgery is the main treatment for chondrosarcoma, chordoma, and giant cell tumor of bone, which can be combined with radiotherapy or targeted therapy. (bvsalud.org)

He serves as Associate Director for Liver Tumor, Kidney Tumor, Germ Cell, and Neuroblastoma Targeted Therapies, and is currently the Sponsor and Study Principal Investigator the CaboMain trial, a Phase 2 study evaluating the efficacy of the oral anticancer agent cabozantinib as a maintenance therapy for ultra-high-risk solid tumors. (spotify.com)
The Cybrexa alphalex™ technology platform - which consists of a pHLIP ® peptide, linker, and small molecule anti-cancer agent (payload) - enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care. (globenewswire.com)
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. (globenewswire.com)
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric antigen receptor (CAR) T-cell therapies for patients with advanced solid tumors. (aacr.org)
Developing CAR T-cell therapies for solid tumors, however, has been challenging, and researchers in the field have had several failed attempts. (aacr.org)
Data presented here at the conference have demonstrated that it is possible to develop CAR T-cell therapies for solid tumors that are not only safe but also yield clinical benefit for patients. (aacr.org)

Immunologic staging performed before and after primary surgery would further help answer the question of whether a patient with a large but regressed tumor can ever be restored to normal immune competence. (cancernetwork.com)
IMC-002 is an immune checkpoint inhibitor antibody, which blocks CD47-SIRP- α interaction between tumor cells and macrophages. (prnewswire.com)
Results showed MDNA11 stimulating the proliferation and activation of anti-cancer CD8+ T cells but not regulatory T cells (Tregs), which are associated with pro-tumor immune pathways. (tmcnet.com)
Investigators reanalyzed this data using a standardized bioinformatics pipeline to identify various signatures that captured cancer cell states, tumor immune inflammation, and immune inhibitory pathways. (genomeweb.com)
According to the authors, two parameters - clonal TMB and the gene CXCL9 - were the strongest predictors across the dataset, beating out other putatively predictive factors including various established gene-expression-based scores of tumor immune response and immune cell infiltration. (genomeweb.com)
Background TNFα is a cytokine produced by immune cells and by tumor cells. (bmj.com)

AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. (wikipedia.org)

Of the 11 patients with NSCLC treated, 2 (18%) had objective responses in tumors that harbor NRAS mutation or BRAF V600E mutation, respectively. (businesswire.com)
Although the addition of radiotherapy did not increase responses vs durvalumab (Imfinzi) and tremelimumab alone for patients with PD-1/PD-L1-refractory metastatic non-small cell lung cancer (NSCLC), select patients may benefit from the PD-L1/CTLA-4 combination, according to findings from a phase 2 study (NCT02888743). (cancernetwork.com)
Recent data suggest that the tumour, node, metastasis classification traditionally reserved for the staging of nonsmall cell lung cancer (NSCLC) can also be applied for the staging of SCLC 3 . (ersjournals.com)
Methods In cohort A, patients with melanoma, RCC, NSCLC or TNBC refractory to standard therapy were treated with IA only. (bmj.com)

Abstract The incidence of primary malignant bone tumors is low, and clinical cognition is insufficient. (bvsalud.org)

SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene's RAF dimer inhibitor, lifirafenib, in combination with SpringWorks' MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberrations. (businesswire.com)
In May, Cybrexa initiated a Phase 1/2 clinical trial to evaluate CBX-12 in patients with advanced or metastatic refractory solid tumors to determine its safety and tolerability, maximum tolerated doses and dose limiting toxicities, and to establish the recommended Phase 2 dose. (globenewswire.com)

An adequate tumor sample must be available from core needle biopsies obtained during the Screening Period and following the subject's most recent systemic therapy. (bcan.org)
It is well known that all these low-dose schedules have a favorable safety profile and may provide an adequate tumor control in patients with metastatic breast cancer. (scirp.org)

The Company's lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I/II in 2021 in advanced solid tumors. (globenewswire.com)

Of the 4 endometrial cancer patients treated, 2 (50%) had objective responses in tumors that harbor BRAF fusion mutation or KRAS mutation, respectively. (businesswire.com)
Some are focusing on small-molecule inhibitors for identifying and targeting key kinases that hamper T-cell responses to tumor cells. (genengnews.com)
Clinical responses included partial responses (PRs) in CPI refractory/resistant patients, including an ongoing confirmed PR in a CPI resistant melanoma patient treated in cohort 2 that remains on study at 10 months. (biospace.com)
As SCLC is a very chemosensitive tumour, rapid responses, with symptomatic improvement, are often seen with chemotherapy. (ersjournals.com)

Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. (memorialcare.org)

The presence of dmin often correlates with a poor prognosis in tumors [ 3 ]. (hindawi.com)
The establishment of diagnostic criteria is of great significance for prognosis of tumors. (bvsalud.org)

[ 1 ] This coverage decision is the culmination of widespread enthusiasm for precision oncology-heightened by the first tissue agnostic approval-the use of pembrolizumab in MSI-high solid tumors, and by reports of dramatic response in diverse cancers to a tropomyosin receptor kinase inhibitor. (medscape.com)

unfortunately, with time almost all prostate cancers will become androgen refractory. (urotoday.com)
Together, they provide us with unique combinatorial flexibility to develop potentially synergistic treatments for a wide range of solid tumors and blood cancers. (biospace.com)
Utility asks: Do cancer patients with relapsed and refractory solid cancers of diverse histology benefit from the use of this test over standard of care? (medscape.com)

The purpose of this study is to find the highest dose of the investigational drug RLY-2608 that can be used alone in people with advanced solid tumors and with fulvestrant in people with advanced breast cancer. (mskcc.org)
Participants must have an advanced solid tumor or breast cancer which contains a PIK3CA mutation. (mskcc.org)
Genomic amplification of FLT3 has been reported in solid tumors including colorectal cancer, breast cancer, and gastric cancer [ 9 ]. (hindawi.com)

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. (bcan.org)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D). (bcan.org)
This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. (bcan.org)
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. (newswise.com)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. (nature.com)
As a result, the RGX-104/docetaxel regimen is being evaluated in a phase 1b/2 expansion study that has begun enrolling patients with relapsed/refractory extensive stage small-cell lung cancer (ES-SCLC) or high grade-neuroendocrine tumors (HG-NET). (biospace.com)
Though we are still in the early stages of the RGX-104 Phase 1b/2 studies, the results show the potential of RGX-104 to provide durable clinical activity in refractory patients through a novel mechanism-of-action. (biospace.com)
As a Phase I cancer trial, this program evaluates the effects of the drug on tumors, as well as its side effects and how the body processes it. (chp.edu)
Our phase 1 CAR T-cell clinical trials against CNS tumors are called BrainChild. (seattlechildrens.org)
STRIvE-01 is a phase 1 trial testing CAR T-cell therapy in children, teens and young adults with relapsed or refractory solid tumors that express the protein EGFR or B7H3. (seattlechildrens.org)

They reported that this score outperformed TMB across a number of tumor-specific datasets, including pan-cancer samples, lung cancer, and melanoma. (genomeweb.com)

Macrophages and lymphocytes produce pro-inflammatory cytokines and chemokines (eg, tumor necrosis factor [TNF]-alpha, granulocyte-macrophage colony-stimulating factor [GM-CSF], various interleukins, interferon-gamma) in the synovium. (msdmanuals.com)

Finally, some are engineering chimeric antigen receptor (CAR) T-cell systems that attack solid tumors and overcome the harsh barriers of the tumor microenvironment (TME). (genengnews.com)
A typical Indukine consists of a wild-type cytokine, an inactivation domain to block activity in the periphery, a tumor-protease-sensitive linker that activates in the tumor microenvironment, and a half-life extension domain. (genengnews.com)

The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. (bcan.org)
Part 1A: Participants with solid tumors where anti-PD-(L)1 is an established treatment. (who.int)

He urged consideration of cyclical maintenance therapy or reinduction therapy, especially in the presence of positive tumor markers. (cancernetwork.com)
He said that the use of tumor markers as an indication for reinduction chemotherapy before obvious clinical relapse could be a welcome new major development. (cancernetwork.com)
Pre- and post-treatment tumor biopsies were analyzed for tumor markers and TILs by immunohistochemistry. (bmj.com)

To be eligible for the dose-escalation portion of the study, patients needed to be 18 years of age or older with either advanced unresectable solid tumors (n = 67) or relapsed/refractory DLBCL (n = 2). (oncnursingnews.com)

I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA). (clinicaltrialsgps.com)
He also consults on patients for precision oncology, partnering with the Institute for Genomic Medicine to identify therapeutic approaches based on patient tumor and germline genomics. (spotify.com)

CNS tumors are brain and spinal cord tumors, such as atypical teratoid/rhabdoid tumor (ATRT), diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). (seattlechildrens.org)
Is CAR T-cell therapy safe to give to children and young adults with relapsed or refractory CNS tumors (tumors of the brain or spinal cord)? (seattlechildrens.org)

Subjects with primary central nervous system (CNS) tumors or clinically active CNS metastases or carcinomatous meningitis. (bcan.org)

Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. (bcan.org)

The lifirafenib plus mirdametinib combination represents a novel targeted approach to treat solid tumors driven by RAS/RAF mutations, and other MAPK pathway aberrations. (businesswire.com)

DLBCL is an aggressive subtype, with up to 50% of high-risk patients experiencing progression after first-line treatment (e.g., relapsing or refractory to treatment). (biospace.com)
The present review addresses the systemic tumour-directed treatment of ES-SCLC. (ersjournals.com)
If this approach is successful, 2 million patients with mesothelin-expressing solid tumors per year in the United States will be eligible for this treatment," said Prasad S. Adusumilli, MD , who presented the study. (aacr.org)
Historically, most cytotoxic treatment regimens have been developed to be used at its maximum tolerated dose (MTD), in order to achieve better tumor control. (scirp.org)
Network (NCCN) regularly publishes "Clinical Practice Guidelines for Bone Tumors" to summarize the latest treatment progress of bone tumors. (bvsalud.org)
The guidelines provide a reference for the standard treatment of bone tumors. (bvsalud.org)

Ewing sarcoma and Ewing-like tumors. (bvsalud.org)

Genetic tests look at the unique genetic material (genes) of patients' tumor cells. (memorialcare.org)
Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. (mayoclinic.org)
This results in killing tumor cells. (mayoclinic.org)
Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mayoclinic.org)
Targeted blockade of the checkpoint molecule programmed cell death 1 (PD-1) can activate tumor-specific T cells to destroy tumors, whereas targeted potentiation of PD-1 is expected to suppress autoreactive T cells and alleviate autoimmune diseases. (nature.com)
RGX-104 inhibits tumor angiogenesis and depletes myeloid derived suppressor cells (MDSC), thereby activating cytotoxic T-lymphocytes. (biospace.com)
The study found that CBX-12 displays pH selectivity, stability in plasma and selective delivery of exatecan to tumor cells versus healthy tissue. (globenewswire.com)
Dependence on antigens is a major barrier to the development of effective cancer therapeutics, and this study supports Cybrexa's approach to delivering exatecan selectively to tumor cells in an antigen-independent manner," said Vishwas Paralkar, Ph.D., Chief Scientific Officer of Cybrexa. (globenewswire.com)
This recent review article summarizes the challenges with developing CAR T-cell therapy for solid tumors and strategies to overcome the hurdles, and lists some of the ongoing clinical trials in which CAR T cells that target tumor antigens, including GD2, CEA, and EGFR, are being currently tested against a variety of solid tumors. (aacr.org)
The team also worked to deliver the CAR T cells directly to the tumor site using regional delivery techniques. (aacr.org)
This is the first CAR T-cell clinical trial using CAR T cells that target four tumor targets. (seattlechildrens.org)
What is the best dose of intracranially-delivered CAR T cells for children and young adults with CNS tumors? (seattlechildrens.org)

At its 17th annual symposium, in what he termed an op-ed piece, Dr. Greenspan, clinical professor of medicine, Mt. Sinai School of Medicine, highlighted what he considers the blind spots and halos in adult solid tumor chemotherapy. (cancernetwork.com)

It also helped to open a very exciting avenue of research involving investigators with expertise in different aspects of growth control and cancer.Giordano's lab also discovered the tumor suppressor gene RB2/p130 and the cell cycle kinases CDK9 and CDK10, two other key players in cell cycle regulation and cell differentiation. (newswise.com)
Patients with PD-1/PD-L1-refractory metastatic non-small cell lung cancer did not achieve additional benefit when radiotherapy was added to durvalumab and tremelimumab. (cancernetwork.com)
In lymph node metastatic prostate cancer ADT improves overall survival if the primary tumor is removed but has no significant effect if the primary tumor is not removed. (urotoday.com)
Daniel Carrizosa, MD, MS, oncologist, Head and Neck Cancer Lung Cancer, Hematology and Medical Oncology (Cancer), Atrium Health Levine Cancer Institute (Thoracic-Pulmonary), discusses the prevalence of NRG1 gene fusions in solid tumors. (onclive.com)
The 2 most common solid tumors to harbor NRG1 fusions are KRAS wild-type pancreatic adenocarcinoma and non-small cell lung cancer, specifically mucinous adenocarcinoma, Carrizosa says. (onclive.com)
Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. (ersjournals.com)
In the metastatic pancreatic cancer patient who had previously achieved a confirmed partial response, tumor reduction of both target lesions continued. (tmcnet.com)

Lenalidomide is well-tolerated at doses up to 70 mg/m(2)/d for 21 days in children with solid tumors. (nih.gov)

The recently-opened third cohort is comprised of patients with relapsed/refractory DLBCL who are receiving the agent at the 30-mg dose. (oncnursingnews.com)

Although these rare fusions occur in approximately 0.2% of all solid tumors, at least 10 different solid tumors have been found to harbor them, Carrizosa adds. (onclive.com)

Extending these promising findings to solid tumors faces substantial hurdles from drug uptake to clinical trial design. (aacrjournals.org)

Anatomy10

Organisms9

Diseases79

Chemicals and Drugs64

Analytical, Diagnostic and Therapeutic Techniques and Equipment62

Phenomena and Processes39

Disciplines and Occupations1

Technology, Industry, Agriculture2

Information Science4

Health Care13

Multiple Myeloma1

Children and adolescents with relapsed1

Advanced solid tumors and relapsed4

Relapsed or refractory disease1

Brain and spinal tumors1

Types of solid tumors1

Lymphoma6

Mutational6

Pediatric5

Recurrent5

Immunotherapy6

Anti-tumor activity3

Cohorts6

Epithelial ovarian cancer3

Myelodysplastic2

Antitumor5

20201

Therapies6

Immune6

20231

NSCLC4

Malignant1

Patients with Advanced2

Adequate tumor2

20211

Responses4

Lymphomas1

Prognosis2

Inhibitor1

Cancers3

Breast cancer3

Phase10

Melanoma1

Necrosis1

Microenvironment2

Participants2

Markers3

Unresectable1

Genomics2

Spinal2

Metastases1

Histologically1

Mutations1

Treatment6

Sarcoma1

Cells12

Chemotherapy1

Cancer7

Lenalidomide1

Cohort1

Harbor1

Hurdles1